Skip to content
Study details
Enrolling now

A Study of KK2269 in Adult Participants With Solid Tumors

Kyowa Kirin Co., Ltd.
NCT IDNCT06266299ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

71

Study length

about 4 years

Ages

18+

Locations

7 sites in AZ, CA, FL +3

What this study is about

Researchers are testing a new drug called KK2269 to see if it's safe and well-tolerated. The trial will involve adults with advanced or metastatic solid tumors for which no standard therapy is available. It is also investigating the safety of KK2269 when combined with docetaxel in patients who have already received other treatments.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Docetaxel
  • 2.Take KK2269

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

docetaxel

Drug routes

infusion

Endpoints

Primary: Number of Adverse Events, Number of Subjects Experiencing Dose-limiting Toxicity

Body systems

Oncology